not going to sit here for months sold.
Market Pulse Archives
May 21, 2013, 11:43 a.m. EDTGoogle extends lead in display ads; Facebook slips
( Just Got Back in GILD and Saw This, Had To Post, Looks Great )
3 Upgrades on Friday Worth Noting
By Brian Nichols - May 20, 2013 |
This Pharma Company Just Keeps Getting Better
Gilead Sciences (NASDAQ: GILD) had seen a bit of a pullback on Thursday, but then erased those losses with gains on Friday after UBS raised its price target to $67 and reiterated its “Buy” rating. The company dominates the HIV market, among others (including an upcoming entrance into oncology), and after a survey of top-volume prescribers the firm is optimistic of the company’s TAF HIV treatment.
The firm went on to say that it could be a next-generation replacement for Viread. As an investor, I take analyst calls more seriously where channel checks or surveys are performed, as they indicate future trends. Gilead is a monster of a company and is well on its way to becoming the next Pfizer. The company controls every industry where it develops drugs, and I agree with UBS, and believe that $67 is a generous target if in fact TAF will be as warmly welcomed as expected
That was May 15th and Next Day Went Up Over $1.00 Now Back for Entry Point fo ASCO. Will be Holding Until After ASCO. Run-Up Then Great Media Blitz on New Cancer Drug $$$$ Guys.
2013 FDA Drug Approval Calendar
BY Adam Feuerstein | 05/21/13
plus Tumblr loses money every year- fb revenue 1.46 Billion.
they don't like the messanger
that's funny cause they sold AFTER tApril 15th. So your answer is wrong.
I think your a short and I think your about to get run over.
buy now and double to triple your money.
takeoff!!
shorts couldn't hold this down..up up and away.
will all be heros here.
says it all.. FDA will also be the heros.
you were right I was wrong,,I just covered and went long. That's for your help.